Advances in systemic therapy for non-small cell lung cancer

ABSTRACTLung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgic...

Full description

Saved in:
Bibliographic Details
Published inBMJ (Online) Vol. 375; p. n2363
Main Authors Miller, Meagan, Hanna, Nasser
Format Journal Article
LanguageEnglish
Published London British Medical Journal Publishing Group 09.11.2021
BMJ Publishing Group LTD
Subjects
20th century
Cancer therapies
Chemoradiotherapy
Chemotherapy
Clinical medicine
Clinical Review
Clinical trials
Cytotoxicity
Immunotherapy
Lung cancer
Metastasis
Mutation
Non-small cell lung carcinoma
Patients
Radiation therapy
Small cell lung carcinoma
Surgery
United States > US
Online AccessGet full text
ISSN1756-1833
1756-1833
DOI10.1136/bmj.n2363

Cover

Abstract ABSTRACTLung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC.
AbstractList Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC.
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC.Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC.
ABSTRACTLung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung cancer (NSCLC) remains an incurable disease for most patients. The optimal treatment for all patients with locally advanced, but surgically resectable, NSCLC contains at least chemoradiation. Trimodality treatment with surgical resection has been a subject of debate for decades. For patients with unresectable or inoperable locally advanced disease, the incorporation of immunotherapy consolidation after chemoradiation has defined a new standard of care. For decades, the standard of care treatment for advanced stage NSCLC included only cytotoxic chemotherapy. However, with the introduction of targeted therapies and immunotherapy, the landscape of treatment has rapidly evolved. This review discusses the integration of these innovative therapies in the management of patients with newly diagnosed NSCLC.
Author Miller, Meagan
Hanna, Nasser
Author_xml – sequence: 1
  givenname: Meagan
  surname: Miller
  fullname: Miller, Meagan
  email: meaemill@iu.edu
– sequence: 2
  givenname: Nasser
  surname: Hanna
  fullname: Hanna, Nasser
BookMark eNptkF9LwzAUxYNM3Jx78BsURNCHbklvk6b4NIb_YOCLPpc0TTWjTWbSCvv2pk5Epi_3Xi6_c8_lnKKRsUYhdE7wnBBgi7LdzE0CDI7QhGSUxYQDjH7NYzTzfoMxTiDjOaMnaAxpRiEjdIJultWHMFL5SJvI73ynWi2j7k05sd1FtXVRsIt9K5omkiqUpjevkRwk7gwd16Lxavbdp-jl7vZ59RCvn-4fV8t1XEKCuxgYTetMpaWoqMQ4pTzjZUVKWUFe5yBLynDCFc95meQcMJcVVVhyUKzmWSCm6Gp_d-vse698V7TaD88Io2zvi4TmDBNIcgjoxQG6sb0z4buBopxyoCRQiz0lnfXeqbqQuhOdtqZzQjcFwcUQbRGiLb6iDYrrA8XW6Va43b_s5Z4dVj_2f7lPXb6Eiw
CitedBy_id crossref_primary_10_3389_fonc_2024_1428307
crossref_primary_10_1186_s13020_024_00904_2
crossref_primary_10_20517_cdr_2024_166
crossref_primary_10_1016_j_biopha_2023_115071
crossref_primary_10_3389_fmed_2023_1201468
crossref_primary_10_3389_fgene_2022_1017866
crossref_primary_10_4103_jcrt_jcrt_167_22
crossref_primary_10_1186_s12885_025_13747_3
crossref_primary_10_1007_s00520_024_08556_6
crossref_primary_10_1016_j_heliyon_2024_e29404
crossref_primary_10_3389_fimmu_2023_1147528
crossref_primary_10_1186_s12920_023_01748_9
crossref_primary_10_3389_fimmu_2022_1040668
crossref_primary_10_3389_fvets_2023_1208538
crossref_primary_10_1016_j_jnutbio_2022_109211
crossref_primary_10_3390_biomedicines12061239
crossref_primary_10_1016_j_heliyon_2024_e37954
crossref_primary_10_1016_j_ejmech_2024_116952
crossref_primary_10_1093_ejcts_ezae071
crossref_primary_10_1186_s12904_024_01459_7
crossref_primary_10_3389_fphar_2024_1385565
crossref_primary_10_23736_S1824_4785_24_03535_0
crossref_primary_10_1186_s12890_023_02707_x
crossref_primary_10_1002_tox_24026
crossref_primary_10_1016_j_intimp_2024_113564
crossref_primary_10_1021_acsnano_3c12694
crossref_primary_10_3390_pharmaceutics15082061
crossref_primary_10_1007_s00432_022_04462_8
crossref_primary_10_1007_s11655_024_4116_7
crossref_primary_10_1186_s12890_023_02722_y
crossref_primary_10_3389_fimmu_2022_906420
crossref_primary_10_3389_fimmu_2022_991091
crossref_primary_10_1111_1759_7714_14919
crossref_primary_10_20517_2394_4722_2023_111
crossref_primary_10_1016_j_cclet_2024_109734
crossref_primary_10_1016_j_critrevonc_2024_104284
crossref_primary_10_1016_j_drup_2023_101032
crossref_primary_10_1002_cam4_7283
crossref_primary_10_18632_aging_206086
crossref_primary_10_1016_j_jvir_2024_10_023
crossref_primary_10_1111_1759_7714_15328
crossref_primary_10_1186_s12890_024_03438_3
crossref_primary_10_1002_msp2_17
crossref_primary_10_3389_fimmu_2023_1148692
crossref_primary_10_1038_s41392_023_01576_4
crossref_primary_10_3346_jkms_2024_39_e16
crossref_primary_10_3390_cancers14143478
crossref_primary_10_1038_s41392_024_02045_2
crossref_primary_10_1186_s12885_024_13155_z
crossref_primary_10_3389_fphar_2023_1250893
crossref_primary_10_1002_cam4_70518
crossref_primary_10_2217_bmm_2021_0919
crossref_primary_10_3389_fonc_2024_1495200
crossref_primary_10_1007_s00432_023_05251_7
crossref_primary_10_1007_s13258_023_01436_z
crossref_primary_10_1016_j_gendis_2025_101536
crossref_primary_10_3389_fchem_2023_1124448
crossref_primary_10_3390_curroncol29120757
crossref_primary_10_1007_s00203_023_03636_3
crossref_primary_10_3389_fphar_2022_1007429
crossref_primary_10_1038_s41419_022_05510_4
crossref_primary_10_3390_biom14070741
crossref_primary_10_1016_j_colsurfb_2023_113344
crossref_primary_10_1186_s12885_024_12456_7
crossref_primary_10_1002_cam4_70473
crossref_primary_10_1016_j_snb_2023_133765
crossref_primary_10_1155_2022_9938936
crossref_primary_10_1186_s13046_023_02936_2
crossref_primary_10_2147_IJGM_S430408
crossref_primary_10_3389_fimmu_2022_845217
crossref_primary_10_7717_peerj_14996
crossref_primary_10_1111_1759_7714_15152
crossref_primary_10_1007_s00432_023_05554_9
crossref_primary_10_3389_fgene_2022_1078790
crossref_primary_10_1111_crj_13805
crossref_primary_10_3389_fonc_2022_924144
crossref_primary_10_1038_s41419_024_07197_1
crossref_primary_10_31083_j_fbl2812357
crossref_primary_10_3389_fimmu_2023_1274547
crossref_primary_10_1007_s00204_022_03404_0
crossref_primary_10_1016_j_survophthal_2023_10_002
crossref_primary_10_3390_molecules28155746
crossref_primary_10_1186_s12951_023_01958_4
crossref_primary_10_1186_s12890_023_02712_0
crossref_primary_10_1186_s12935_023_03204_1
crossref_primary_10_3389_fphar_2025_1511171
crossref_primary_10_1016_j_ymthe_2023_09_015
crossref_primary_10_3389_fphar_2022_979951
crossref_primary_10_3390_ijms23031785
crossref_primary_10_1039_D4NR00230J
crossref_primary_10_3390_biomedicines11123133
crossref_primary_10_4046_trd_2024_0087
crossref_primary_10_1002_cbf_3902
crossref_primary_10_3389_fmed_2024_1491337
crossref_primary_10_1080_02648725_2023_2196155
crossref_primary_10_3390_molecules28135152
crossref_primary_10_1007_s10735_023_10148_3
crossref_primary_10_1002_lpor_202401400
crossref_primary_10_3389_fimmu_2025_1555216
crossref_primary_10_1080_02656736_2022_2154577
crossref_primary_10_7759_cureus_57820
crossref_primary_10_2174_0113816128330530240918073721
crossref_primary_10_1007_s10238_024_01439_4
crossref_primary_10_1055_a_2458_7088
crossref_primary_10_62347_FGAY1920
crossref_primary_10_1186_s10020_024_00813_y
crossref_primary_10_3389_fphar_2024_1289957
crossref_primary_10_1016_j_canlet_2024_217266
crossref_primary_10_1002_cbin_12197
crossref_primary_10_1186_s12935_023_03082_7
crossref_primary_10_3389_fmed_2024_1497312
crossref_primary_10_1158_1078_0432_CCR_24_0741
crossref_primary_10_1007_s00066_024_02221_x
crossref_primary_10_1016_j_procbio_2022_05_028
crossref_primary_10_3892_ol_2024_14598
crossref_primary_10_1111_1759_7714_15235
crossref_primary_10_3389_fmed_2023_1191019
crossref_primary_10_18632_aging_205464
crossref_primary_10_3389_fchem_2022_837987
crossref_primary_10_1007_s10142_023_01260_4
crossref_primary_10_1016_j_phrs_2023_107034
crossref_primary_10_1016_j_biopha_2024_117102
crossref_primary_10_3390_ijms25179147
crossref_primary_10_5897_AJPP2021_5289
crossref_primary_10_1002_adma_202308977
crossref_primary_10_3892_ijo_2024_5690
crossref_primary_10_1186_s13046_025_03315_9
crossref_primary_10_1515_med_2023_0663
crossref_primary_10_1155_2023_5532617
crossref_primary_10_1016_j_ajps_2023_100833
crossref_primary_10_3389_fimmu_2023_1202822
crossref_primary_10_1038_s41420_024_02220_y
crossref_primary_10_1002_ccr3_7365
crossref_primary_10_1016_j_ajpath_2022_06_015
crossref_primary_10_3389_fphar_2024_1363346
crossref_primary_10_3389_fphar_2023_1238579
crossref_primary_10_1097_MD_0000000000035341
crossref_primary_10_3892_mco_2024_2726
crossref_primary_10_1186_s12885_025_13859_w
crossref_primary_10_54097_hset_v8i_1115
crossref_primary_10_3389_fonc_2022_1029738
crossref_primary_10_1002_adbi_202400119
crossref_primary_10_3389_fonc_2023_1110917
crossref_primary_10_3390_cancers14194709
crossref_primary_10_3390_cancers16183193
crossref_primary_10_3389_fonc_2023_1213273
crossref_primary_10_18632_aging_205049
crossref_primary_10_3390_medicina60020236
crossref_primary_10_1155_2022_4090346
crossref_primary_10_1080_1120009X_2022_2162218
crossref_primary_10_3389_fonc_2024_1458374
crossref_primary_10_1038_s41598_024_76947_0
crossref_primary_10_1172_jci_insight_186165
crossref_primary_10_1111_crj_70023
crossref_primary_10_1186_s12880_024_01221_8
crossref_primary_10_1007_s00262_024_03893_1
crossref_primary_10_1002_jgm_3565
crossref_primary_10_1016_j_abb_2024_110130
crossref_primary_10_3724_abbs_2024082
crossref_primary_10_3389_fonc_2022_1011091
crossref_primary_10_1097_MD_0000000000035837
crossref_primary_10_1111_1759_7714_14385
crossref_primary_10_1002_tox_24282
crossref_primary_10_3390_genes13122295
crossref_primary_10_2217_imt_2023_0268
crossref_primary_10_5812_ijcm_146781
crossref_primary_10_1007_s00595_023_02708_7
crossref_primary_10_3389_fimmu_2023_1171145
crossref_primary_10_1097_MD_0000000000032169
crossref_primary_10_1186_s41065_023_00294_9
crossref_primary_10_1186_s12890_023_02351_5
crossref_primary_10_3389_fphar_2023_1093017
crossref_primary_10_3389_fsurg_2022_964044
crossref_primary_10_3389_fsurg_2022_1038219
crossref_primary_10_3390_jcm11144098
crossref_primary_10_1111_jcmm_70218
crossref_primary_10_3390_ijms252413262
crossref_primary_10_1186_s13578_023_01101_8
crossref_primary_10_1038_s41598_023_46857_8
crossref_primary_10_1186_s12890_023_02809_6
crossref_primary_10_1097_JS9_0000000000001921
crossref_primary_10_1088_1361_6560_ad13d1
crossref_primary_10_3389_fimmu_2022_1017400
crossref_primary_10_1186_s12890_022_02279_2
crossref_primary_10_4103_2311_8571_385513
crossref_primary_10_1186_s12967_024_05423_0
Cites_doi 10.1016/j.annonc.2020.04.478
10.1016/S1470-2045(17)30608-3
10.1056/NEJMoa2027071
10.1200/JCO.18.00149
10.1200/JCO.19.03136
10.1056/NEJMoa2027187
10.1093/annonc/mdy334
10.1200/JCO.2018.36.15_suppl.9007
10.1016/S1470-2045(11)70393-X
10.3389/fphar.2017.00561
10.1007/s00262-020-02714-5
10.1093/annonc/mdz077
10.1200/JCO.19.01154
10.1158/1078-0432.CCR-13-0318
10.1016/j.lungcan.2014.06.007
10.1016/S1470-2045(11)70184-X
10.1056/NEJMoa043623
10.31662/jmaj.2020-0021
10.1056/NEJMoa1910231
10.1056/NEJMoa1810171
10.1200/JCO.2020.38.15_suppl.9500
10.1056/NEJMoa1501824
10.1016/S1470-2045(06)70804-X
10.1016/j.annonc.2020.08.2293
10.1016/S1470-2045(17)30679-4
10.1200/JCO.2007.13.9030
10.1016/j.jtho.2020.12.015
10.1002/cam4.2972
10.1056/NEJMoa1917239
10.1158/1078-0432.CCR-09-0802
10.1093/annonc/mdx091.063
10.1016/S1470-2045(14)71173-8
10.1200/JCO.2009.27.6204
10.1016/S0140-6736(15)60294-X
10.1016/S0140-6736(18)32409-7
10.1056/NEJMoa1406766
10.1200/JCO.2018.36.34_suppl.36
10.1200/JCO.2020.38.15_suppl.9509
10.1016/j.jtho.2019.03.007
10.1056/NEJMoa1704795
10.1200/JCO.19.01488
10.1007/s00520-018-4184-3
10.1186/1472-684X-13-59
10.1164/rccm.200504-531OE
10.1200/JCO.2019.37.15_suppl.9001
10.1200/JCO.2020.38.15_suppl.9515
10.1001/jama.2009.1198
10.1056/NEJMoa1000678
10.1002/j.1460-2075.1992.tb05481.x
10.1200/JCO.2018.77.9777
10.1200/PO.19.00333
10.1016/S1470-2045(14)70381-X
10.1177/0269216317751893
10.1056/NEJMoa1716948
10.1016/j.jtho.2021.01.320
10.1200/JCO.2018.77.7326
10.1200/JCO.2020.38.15_suppl.9504
10.1200/JCO.2020.38.15_suppl.TPS9077
10.1056/NEJMoa2005653
10.1016/j.annonc.2019.10.022
10.1001/jamaoncol.2020.6758
10.1093/annonc/mdr345
10.3322/caac.21492
10.21037/apm-20-270
10.1200/JCO.2005.04.6110
10.1093/annonc/mdv276
10.1056/NEJMoa1801005
10.1200/JCO.2020.38.15_suppl.9514
10.1056/NEJMoa031644
10.1200/JCO.2010.33.7089
10.1056/NEJMoa1606774
10.1016/S1470-2045(19)30035-X
10.1016/j.annonc.2020.08.2335
10.1200/JCO.20.00131
10.1056/NEJMoa0909530
10.1177/1049909120973200
10.1056/NEJMoa1709937
10.1002/cncr.33083
10.1093/annonc/mdv573
10.1093/annonc/mdy542
10.1056/NEJMoa1810865
10.1016/S0140-6736(13)62159-5
10.1055/s-0033-1342949
10.1093/annonc/mdx359
10.1016/S1470-2045(19)30634-5
10.1016/S1470-2045(19)30167-6
10.1056/NEJMoa1716078
10.1016/S0140-6736(09)60737-6
10.1016/j.jpainsymman.2016.01.003
10.1038/70932
10.1056/NEJMoa1503093
10.1200/JCO.2019.37.15_suppl.9092
10.1016/j.jtho.2018.03.035
10.1200/JCO.2013.50.5016
10.1200/JCO.2020.38.15_suppl.9513
10.1200/JCO.2020.38.15_suppl.9512
10.1093/annonc/mdy424.090
10.1200/JCO.2020.38.15_suppl.9501
10.1200/JCO.2011.39.4882
10.1016/S1470-2045(19)30690-4
10.1200/JCO.2016.71.3701
10.3816/CLC.2006.n.001
10.1093/annonc/mdz131
10.1056/NEJMoa1713137
10.1200/JCO.2020.38.15_suppl.9580
10.1056/NEJMoa1913662
10.1016/S0140-6736(17)30565-2
10.1016/S0140-6736(21)00228-2
10.1200/JCO.2019.37.15_suppl.8526
10.1016/j.annonc.2020.08.2280
10.1200/JCO.20.00505
10.1056/NEJMoa2004407
10.4143/crt.2019.186
10.1093/annonc/mdv270
ContentType Journal Article
Copyright Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go tohttp://group.bmj.com/group/rights-licensing/permissions2021BMJ
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Copyright_xml – notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to
– notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go tohttp://group.bmj.com/group/rights-licensing/permissions2021BMJ
– notice: Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
DBID AAYXX
CITATION
3V.
7RV
7X7
7XB
88I
8AF
8FE
8FH
8FI
8FJ
8FK
8G5
ABUWG
AFKRA
ASE
AZQEC
BBNVY
BENPR
BHPHI
BTHHO
CCPQU
DWQXO
FPQ
FYUFA
GHDGH
GNUQQ
GUQSH
HCIFZ
K6X
K9.
KB0
LK8
M2O
M2P
M7P
MBDVC
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
DOI 10.1136/bmj.n2363
DatabaseName CrossRef
ProQuest Central (Corporate)
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Science Database (Alumni Edition)
STEM Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Index
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
BMJ Journals
ProQuest One Community College
ProQuest Central Korea
British Nursing Index (BNI) (1985 to Present)
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Research Library
SciTech Premium Collection
British Nursing Index
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
Research Library (ProQuest)
Science Database
Biological Science Database
Research Library (Corporate)
Nursing & Allied Health Premium
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
DatabaseTitle CrossRef
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest AP Science
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Research Library
ProQuest Central (New)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
British Nursing Index
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
BMJ Journals
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Research Library Prep
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-1833
ExternalDocumentID 10_1136_bmj_n2363
bmj
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GroupedDBID 23N
39C
4.4
40O
53G
5GY
7RV
7X7
88I
8AF
8F7
8FE
8FH
8FI
8FJ
8G5
AACGO
AANCE
AAWJN
ABIVO
ABJNI
ABPLY
ABTLG
ABUWG
ABVAJ
ACGFS
ACGOD
ACMFJ
ACPRK
AFKRA
AGFXO
AHMBA
AHNKE
AHQMW
AJYBZ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BBNVY
BENPR
BHPHI
BPHCQ
BTHHO
C45
CCPQU
CS3
DWQXO
EBS
EJD
F5P
FYUFA
GNUQQ
GUQSH
H13
HAJ
HCIFZ
HMCUK
HZ~
JLS
JSG
JST
L7B
LK8
M2O
M2P
M7P
NAPCQ
NXWIF
O9-
OVD
PHGZT
PQQKQ
PROAC
R53
RHI
RMJ
RV8
TEORI
UKHRP
VVN
WOQ
YFH
YQY
AAYXX
CITATION
PHGZM
3V.
7XB
8FK
ASE
FPQ
K6X
K9.
MBDVC
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
ID FETCH-LOGICAL-b320t-3654f7e4bad5c0045878bd1bcd39f93cb56028e898b298308cd5e0c83e6f87f93
IEDL.DBID 7X7
ISSN 1756-1833
IngestDate Fri Jul 11 00:40:05 EDT 2025
Fri Jul 25 11:45:40 EDT 2025
Thu Apr 24 23:08:13 EDT 2025
Tue Jul 01 02:24:09 EDT 2025
Thu Apr 24 22:49:52 EDT 2025
IsPeerReviewed true
IsScholarly true
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b320t-3654f7e4bad5c0045878bd1bcd39f93cb56028e898b298308cd5e0c83e6f87f93
Notes State of the Art Review
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
PMID 34753715
PQID 2595858351
PQPubID 2043523
ParticipantIDs proquest_miscellaneous_2596013293
proquest_journals_2595858351
crossref_citationtrail_10_1136_bmj_n2363
crossref_primary_10_1136_bmj_n2363
bmj_journals_10_1136_bmj_n2363
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20211109
2021-11-09
PublicationDateYYYYMMDD 2021-11-09
PublicationDate_xml – month: 11
  year: 2021
  text: 20211109
  day: 9
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle BMJ (Online)
PublicationTitleAbbrev BMJ
PublicationYear 2021
Publisher British Medical Journal Publishing Group
BMJ Publishing Group LTD
Publisher_xml – name: British Medical Journal Publishing Group
– name: BMJ Publishing Group LTD
References Paik, Felip, Veillon (ref69) 2020; 383
Jassem, Marinis, Spigel (ref94) 2017; 28
Sabari, Leonardi, Shu (ref70) 2018; 29
Spiro, Silvestri (ref1) 2005; 172
Seto, Nishio, Hida (ref58) 2019; 37
Adderley, Blackhall, Lindsay (ref45) 2021; 70
Shaw, Riely, Bang (ref86) 2019; 30
Socinski (ref48) 2020; 31
Reck, Rodríguez-Abreu, Robinson (ref92) 2019; 37
Lim, Kim, Lee (ref65) 2017; 35
Ridge, McErlean, Ginsberg (ref2) 2013; 30
(ref4) 2018; 68
Robert, Schachter, Long (ref104) 2015; 372
Enguidanos, Cardenas, Wenceslao (ref115) 2021; 38
(ref14) 2014; 383
Peters, Camidge, Shaw (ref54) 2017; 377
Temel, Pirl, Lynch (ref107) 2006; 7
Rodig, Mino-Kenudson, Dacic (ref52) 2009; 15
Zhou, Wu, Chen (ref31) 2015; 26
Gadgeel, Rodríguez-Abreu, Speranza (ref97) 2020; 38
Lee, Jung, Sun (ref79) 2020; 52
Hosomi, Morita, Sugawara (ref40) 2020; 38
Shaw, Ou, Bang (ref63) 2014; 371
Smit, Nakagawa, Nagasaka (ref82) 2020; 38
Ishida, Agata, Shibahara, Honjo (ref88) 1992; 11
Hellmann, Paz-Ares, Bernabe Caro (ref101) 2019; 381
Albain, Swann, Rusch (ref15) 2009; 374
Pless, Stupp, Ris (ref16) 2015; 386
Slotman (ref5) 2011; 1
Noronha, Patil, Joshi (ref39) 2020; 38
Gainor, Varghese, Ou (ref53) 2013; 19
Drilon, Siena, Dziadziuszko (ref64) 2020; 21
Wolf, Overbeck, Han (ref68) 2020; 38
Douillard, Rosell, De Lena (ref7) 2006; 7
Horn, Lin, Padda (ref50) 2020; 38
Falchook, Ordóñez, Bastida (ref72) 2016; 34
Le Pechoux, Pourel, Barlesi (ref11) 2020; 31
Charalambous, Pallis, Hasan, O’Brien (ref114) 2014; 13
Schaake, Kappers, Codrington (ref18) 2012; 30
Park, John, Kim (ref51) 2020; 38
Maemondo, Inoue, Kobayashi (ref28) 2010; 362
Sands, Mandrekar, Oxnard (ref25) 2020; 38
Gray, Villegas, Daniel (ref22) 2019; 37
Mazières, Barlesi, Filleron (ref80) 2016; 27
Wu, Zhang, Kim (ref66) 2018; 36
Reck, Rodríguez-Abreu, Robinson (ref91) 2016; 375
King, Eickhoff, Traynor, Campbell (ref111) 2016; 51
Felip, Rosell, Maestre (ref12) 2010; 28
Wolf, Seto, Han (ref67) 2018; 29
Reck, Ciuleanu, Dols (ref102) 2020; 38
Soria, Ohe, Vansteenkiste (ref35) 2018; 378
Seto, Kato, Nishio (ref42) 2014; 15
Mok, Wu, Kudaba (ref93) 2019; 393
Shi, Wang, Han (ref33) 2017; 28
Akamatsu, Toi, Hayashi (ref44) 2021; 7
Hida, Nokihara, Kondo (ref57) 2017; 390
Saito, Fukuhara, Furuya (ref38) 2019; 20
Wu, Zhou, Liam (ref32) 2015; 26
Forde, Chaft, Smith (ref17) 2018; 378
Wu, Tsuboi, He (ref19) 2020; 383
Zhao, Xia (ref81) 2020; 4
Antonia, Villegas, Daniel (ref21) 2017; 377
Piotrowska, Wang, Sequist, Ramalingam (ref47) 2020; 38
Planchard, Smit, Groen (ref75) 2017; 18
Waterhouse, Garon, Chandler (ref106) 2020; 38
Nakagawa, Garon, Seto (ref37) 2019; 20
Bray, Ferlay, Soerjomataram, Siegel, Torre, Jemal (ref3) 2018; 68
Li, Shen, Buonocore (ref77) 2018; 36
Rosell, Carcereny, Gervais (ref29) 2012; 13
Paz-Ares, Luft, Vicente (ref98) 2018; 379
Scagliotti, Pastorino, Vansteenkiste (ref13) 2012; 30
Durm, Jabbour, Althouse (ref24) 2020; 126
Ramalingam, Ciuleanu, Pluzanski (ref103) 2020; 38
Schoenfeld, Arbour, Rizvi (ref46) 2019; 30
Hong, Fakih, Strickler (ref85) 2020; 383
Pignon, Tribodet, Scagliotti (ref8) 2008; 26
Yang, Wu, Schuler (ref27) 2015; 16
Mazieres, Cropet, Montané (ref76) 2020; 31
Camidge, Kim, Ahn (ref60) 2020; 38
Yamamoto, Seto, Nishio (ref43) 2018; 36
Lisberg, Cummings, Goldman (ref26) 2018; 13
Ambroggi, Biasini, Toscani (ref112) 2018; 26
Gainor, Curigliano, Kim (ref74) 2020; 38
Kruser, Kruser, Gross (ref116) 2020; 9
Arriagada, Bergman, Dunant, Le Chevalier, Pignon, Vansteenkiste (ref6) 2004; 350
Socinski, Jotte, Cappuzzo (ref100) 2018; 378
Wu, Cheng, Zhou (ref34) 2017; 18
Wang, Jiang, Qin (ref83) 2019; 30
Temel, Greer, Muzikansky (ref110) 2010; 363
Shaw, Bauer, de Marinis (ref61) 2020; 383
Lally, Zelterman, Colasanto, Haffty, Detterbeck, Wilson (ref10) 2006; 24
Bakitas, Lyons, Hegel (ref108) 2009; 302
Winton, Livingston, Johnson (ref9) 2005; 352
Nipp, El-Jawahri, Traeger (ref109) 2018; 32
Faivre-Finn, Vicente, Kurata (ref23) 2021; 16
West, McCleod, Hussein (ref99) 2019; 20
Gandhi, Rodríguez-Abreu, Gadgeel (ref96) 2018; 378
Noronha, Joshi, Patil (ref41) 2019; 37
Zhou, Wu, Chen (ref30) 2011; 12
Camidge, Dziadziuszko, Peters (ref56) 2019; 14
Drilon, Oxnard, Tan (ref73) 2020; 383
Le, Goldman, Clarke (ref49) 2020; 38
Takahashi, Kawai, Asai (ref71) 2020; 3
Dong, Zhu, Tamada, Chen (ref89) 1999; 5
Steffen, Lycan, Levine (ref117) 2018; 36
Mok, Camidge, Gadgeel (ref55) 2020; 31
Yoshizawa, Sumiyoshi, Sonobe (ref78) 2014; 85
Sezer, Kilickap, Gümüş (ref95) 2021; 397
Laskin, Liu, Tolba (ref84) 2020; 31
Ramalingam, Vansteenkiste, Planchard (ref36) 2020; 382
Smith, Nelson, Berman (ref113) 2012; 23
Alsaab, Sau, Alzhrani (ref90) 2017; 8
Shen, Qiang, Li, Ding, Yu, Lu (ref87) 2020; 9
Camidge, Kim, Ahn (ref59) 2018; 379
Garon, Rizvi, Hui (ref105) 2015; 372
2023030804370732000_375.nov09_3.n2363.55
2023030804370732000_375.nov09_3.n2363.56
2023030804370732000_375.nov09_3.n2363.53
2023030804370732000_375.nov09_3.n2363.54
2023030804370732000_375.nov09_3.n2363.59
2023030804370732000_375.nov09_3.n2363.57
2023030804370732000_375.nov09_3.n2363.58
2023030804370732000_375.nov09_3.n2363.62
2023030804370732000_375.nov09_3.n2363.63
2023030804370732000_375.nov09_3.n2363.60
2023030804370732000_375.nov09_3.n2363.61
2023030804370732000_375.nov09_3.n2363.66
2023030804370732000_375.nov09_3.n2363.67
2023030804370732000_375.nov09_3.n2363.64
2023030804370732000_375.nov09_3.n2363.65
2023030804370732000_375.nov09_3.n2363.68
2023030804370732000_375.nov09_3.n2363.69
2023030804370732000_375.nov09_3.n2363.70
2023030804370732000_375.nov09_3.n2363.73
2023030804370732000_375.nov09_3.n2363.74
2023030804370732000_375.nov09_3.n2363.71
2023030804370732000_375.nov09_3.n2363.72
2023030804370732000_375.nov09_3.n2363.39
2023030804370732000_375.nov09_3.n2363.33
2023030804370732000_375.nov09_3.n2363.34
2023030804370732000_375.nov09_3.n2363.31
2023030804370732000_375.nov09_3.n2363.32
2023030804370732000_375.nov09_3.n2363.37
2023030804370732000_375.nov09_3.n2363.38
2023030804370732000_375.nov09_3.n2363.35
2023030804370732000_375.nov09_3.n2363.36
2023030804370732000_375.nov09_3.n2363.40
2023030804370732000_375.nov09_3.n2363.41
Socinski (2023030804370732000_375.nov09_3.n2363.48) 2020; 31
2023030804370732000_375.nov09_3.n2363.6
2023030804370732000_375.nov09_3.n2363.44
2023030804370732000_375.nov09_3.n2363.7
2023030804370732000_375.nov09_3.n2363.45
2023030804370732000_375.nov09_3.n2363.8
2023030804370732000_375.nov09_3.n2363.42
2023030804370732000_375.nov09_3.n2363.9
2023030804370732000_375.nov09_3.n2363.43
2023030804370732000_375.nov09_3.n2363.2
2023030804370732000_375.nov09_3.n2363.3
2023030804370732000_375.nov09_3.n2363.49
2023030804370732000_375.nov09_3.n2363.4
2023030804370732000_375.nov09_3.n2363.46
2023030804370732000_375.nov09_3.n2363.47
2023030804370732000_375.nov09_3.n2363.1
2023030804370732000_375.nov09_3.n2363.51
2023030804370732000_375.nov09_3.n2363.52
2023030804370732000_375.nov09_3.n2363.50
2023030804370732000_375.nov09_3.n2363.19
2023030804370732000_375.nov09_3.n2363.17
2023030804370732000_375.nov09_3.n2363.18
2023030804370732000_375.nov09_3.n2363.11
2023030804370732000_375.nov09_3.n2363.99
2023030804370732000_375.nov09_3.n2363.12
2023030804370732000_375.nov09_3.n2363.97
2023030804370732000_375.nov09_3.n2363.10
2023030804370732000_375.nov09_3.n2363.98
2023030804370732000_375.nov09_3.n2363.15
2023030804370732000_375.nov09_3.n2363.16
2023030804370732000_375.nov09_3.n2363.100
2023030804370732000_375.nov09_3.n2363.13
Slotman (2023030804370732000_375.nov09_3.n2363.5) 2011; 1
2023030804370732000_375.nov09_3.n2363.14
2023030804370732000_375.nov09_3.n2363.103
2023030804370732000_375.nov09_3.n2363.104
2023030804370732000_375.nov09_3.n2363.101
2023030804370732000_375.nov09_3.n2363.102
2023030804370732000_375.nov09_3.n2363.107
2023030804370732000_375.nov09_3.n2363.108
2023030804370732000_375.nov09_3.n2363.105
2023030804370732000_375.nov09_3.n2363.106
2023030804370732000_375.nov09_3.n2363.109
2023030804370732000_375.nov09_3.n2363.28
2023030804370732000_375.nov09_3.n2363.29
2023030804370732000_375.nov09_3.n2363.22
2023030804370732000_375.nov09_3.n2363.23
2023030804370732000_375.nov09_3.n2363.20
2023030804370732000_375.nov09_3.n2363.21
2023030804370732000_375.nov09_3.n2363.26
2023030804370732000_375.nov09_3.n2363.110
2023030804370732000_375.nov09_3.n2363.27
2023030804370732000_375.nov09_3.n2363.111
2023030804370732000_375.nov09_3.n2363.24
2023030804370732000_375.nov09_3.n2363.25
2023030804370732000_375.nov09_3.n2363.114
2023030804370732000_375.nov09_3.n2363.115
2023030804370732000_375.nov09_3.n2363.112
2023030804370732000_375.nov09_3.n2363.113
2023030804370732000_375.nov09_3.n2363.30
2023030804370732000_375.nov09_3.n2363.116
2023030804370732000_375.nov09_3.n2363.117
2023030804370732000_375.nov09_3.n2363.77
2023030804370732000_375.nov09_3.n2363.78
2023030804370732000_375.nov09_3.n2363.75
2023030804370732000_375.nov09_3.n2363.76
2023030804370732000_375.nov09_3.n2363.79
2023030804370732000_375.nov09_3.n2363.80
2023030804370732000_375.nov09_3.n2363.81
2023030804370732000_375.nov09_3.n2363.84
2023030804370732000_375.nov09_3.n2363.85
2023030804370732000_375.nov09_3.n2363.82
2023030804370732000_375.nov09_3.n2363.83
2023030804370732000_375.nov09_3.n2363.88
2023030804370732000_375.nov09_3.n2363.89
2023030804370732000_375.nov09_3.n2363.86
2023030804370732000_375.nov09_3.n2363.87
2023030804370732000_375.nov09_3.n2363.91
2023030804370732000_375.nov09_3.n2363.92
2023030804370732000_375.nov09_3.n2363.90
2023030804370732000_375.nov09_3.n2363.95
2023030804370732000_375.nov09_3.n2363.96
2023030804370732000_375.nov09_3.n2363.93
2023030804370732000_375.nov09_3.n2363.94
References_xml – volume: 381
  start-page: 2020
  year: 2019
  ident: ref101
  article-title: Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
– volume: 30
  start-page: 1121
  year: 2019
  ident: ref86
  article-title: Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001
  publication-title: Ann Oncol
– volume: 30
  start-page: 2731
  year: 2012
  ident: ref18
  article-title: Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer
  publication-title: J Clin Oncol
– volume: 26
  start-page: 1883
  year: 2015
  ident: ref32
  article-title: First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
  publication-title: Ann Oncol
– volume: 7
  start-page: 386
  year: 2021
  ident: ref44
  article-title: Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial
  publication-title: JAMA Oncol
– volume: 37
  start-page: 537
  year: 2019
  ident: ref92
  article-title: Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
  publication-title: J Clin Oncol
– volume: 26
  start-page: 3552
  year: 2008
  ident: ref8
  article-title: Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group
  publication-title: J Clin Oncol
– volume: 24
  start-page: 2998
  year: 2006
  ident: ref10
  article-title: Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database
  publication-title: J Clin Oncol
– volume: 52
  start-page: 292
  year: 2020
  ident: ref79
  article-title: Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
  publication-title: Cancer Res Treat
– volume: 26
  start-page: 2945
  year: 2018
  ident: ref112
  article-title: Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature
  publication-title: Support Care Cancer
– volume: 85
  start-page: 373
  year: 2014
  ident: ref78
  article-title: HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations
  publication-title: Lung Cancer
– volume: 382
  start-page: 41
  year: 2020
  ident: ref36
  article-title: Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
  publication-title: N Engl J Med
– volume: 302
  start-page: 741
  year: 2009
  ident: ref108
  article-title: Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial
  publication-title: JAMA
– volume: 36
  start-page: 2532
  year: 2018
  ident: ref77
  article-title: Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
  publication-title: J Clin Oncol
– volume: 397
  start-page: 592
  year: 2021
  ident: ref95
  article-title: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
  publication-title: Lancet
– volume: 38
  start-page: 3592
  year: 2020
  ident: ref60
  article-title: Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
  publication-title: J Clin Oncol
– volume: 363
  start-page: 733
  year: 2010
  ident: ref110
  article-title: Early palliative care for patients with metastatic non-small-cell lung cancer
  publication-title: N Engl J Med
– volume: 13
  start-page: 239
  year: 2012
  ident: ref29
  article-title: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
  publication-title: Lancet Oncol
– volume: 38
  start-page: 9500
  year: 2020
  ident: ref103
  article-title: Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1
  publication-title: J Clin Oncol
– volume: 11
  start-page: 3887
  year: 1992
  ident: ref88
  article-title: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
  publication-title: EMBO J
– volume: 383
  start-page: 1561
  year: 2014
  ident: ref14
  article-title: Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
  publication-title: Lancet
– volume: 68
  start-page: 394
  year: 2018
  ident: ref3
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
– volume: 386
  start-page: 1049
  year: 2015
  ident: ref16
  article-title: Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial
  publication-title: Lancet
– volume: 29
  start-page: 2085
  year: 2018
  ident: ref70
  article-title: PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
  publication-title: Ann Oncol
– volume: 28
  start-page: II50
  year: 2017
  ident: ref94
  article-title: IMpower110: Phase III trial of 1L atezolizumab in PD-L1-selected chemotherapy-naïve NSCLC
  publication-title: Ann Oncol
– volume: 38
  start-page: 3863
  year: 2020
  ident: ref106
  article-title: Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153
  publication-title: J Clin Oncol
– volume: 36
  start-page: 3101
  year: 2018
  ident: ref66
  article-title: Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
  publication-title: J Clin Oncol
– volume: 38
  start-page: 115
  year: 2020
  ident: ref40
  article-title: Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
  publication-title: J Clin Oncol
– volume: 38
  start-page: 9509
  year: 2020
  ident: ref68
  article-title: Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study
  publication-title: J Clin Oncol
– volume: 1
  start-page: 63
  year: 2011
  ident: ref5
  article-title: Stereotactic body radiotherapy for stage I non-small cell lung cancer
  publication-title: J Radiosurg SBRT
– volume: 29
  start-page: VIII741
  year: 2018
  ident: ref67
  article-title: Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor Capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)
  publication-title: Ann Oncol
– volume: 378
  start-page: 1976
  year: 2018
  ident: ref17
  article-title: Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
  publication-title: N Engl J Med
– volume: 30
  start-page: 839
  year: 2019
  ident: ref46
  article-title: Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib
  publication-title: Ann Oncol
– volume: 30
  start-page: 93
  year: 2013
  ident: ref2
  article-title: Epidemiology of lung cancer
  publication-title: Semin Intervent Radiol
– volume: 383
  start-page: 931
  year: 2020
  ident: ref69
  article-title: Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
  publication-title: N Engl J Med
– volume: 14
  start-page: 1233
  year: 2019
  ident: ref56
  article-title: Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study
  publication-title: J Thorac Oncol
– volume: 38
  start-page: 1505
  year: 2020
  ident: ref97
  article-title: Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
  publication-title: J Clin Oncol
– volume: 372
  start-page: 2521
  year: 2015
  ident: ref104
  article-title: Pembrolizumab versus Ipilimumab in Advanced Melanoma
  publication-title: N Engl J Med
– volume: 38
  start-page: 9580
  year: 2020
  ident: ref50
  article-title: Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions
  publication-title: J Clin Oncol
– volume: 20
  start-page: 1655
  year: 2019
  ident: ref37
  article-title: Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
  publication-title: Lancet Oncol
– volume: 126
  start-page: 4353
  year: 2020
  ident: ref24
  article-title: A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179
  publication-title: Cancer
– volume: 16
  start-page: 860
  year: 2021
  ident: ref23
  article-title: Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial
  publication-title: J Thorac Oncol
– volume: 383
  start-page: 1207
  year: 2020
  ident: ref85
  article-title: KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
  publication-title: N Engl J Med
– volume: 20
  start-page: 924
  year: 2019
  ident: ref99
  article-title: Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
  publication-title: Lancet Oncol
– volume: 38
  start-page: 1112
  year: 2021
  ident: ref115
  article-title: Health Care Provider Barriers to Patient Referral to Palliative Care
  publication-title: Am J Hosp Palliat Care
– volume: 70
  start-page: 589
  year: 2021
  ident: ref45
  article-title: Toxicity with small molecule and immunotherapy combinations in non-small cell lung cancer
  publication-title: Cancer Immunol Immunother
– volume: 38
  start-page: 9512
  year: 2020
  ident: ref51
  article-title: Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC)
  publication-title: J Clin Oncol
– volume: 51
  start-page: 1027
  year: 2016
  ident: ref111
  article-title: Integrated Onco-Palliative Care Associated With Prolonged Survival Compared to Standard Care for Patients With Advanced Lung Cancer: A Retrospective Review
  publication-title: J Pain Symptom Manage
– volume: 31
  start-page: S1142
  year: 2020
  ident: ref48
  article-title: LBA60 - ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
  publication-title: Ann Oncol
– volume: 31
  start-page: S1178
  year: 2020
  ident: ref11
  article-title: An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683
  publication-title: Ann Oncol
– volume: 37
  start-page: 8526
  year: 2019
  ident: ref22
  article-title: Three-year overall survival update from the PACIFIC trial
  publication-title: J Clin Oncol
– volume: 23
  start-page: 382
  year: 2012
  ident: ref113
  article-title: Lung cancer physicians’ referral practices for palliative care consultation
  publication-title: Ann Oncol
– volume: 35
  start-page: 2613
  year: 2017
  ident: ref65
  article-title: Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement
  publication-title: J Clin Oncol
– volume: 12
  start-page: 735
  year: 2011
  ident: ref30
  article-title: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
  publication-title: Lancet Oncol
– volume: 9
  start-page: 3310
  year: 2020
  ident: ref87
  article-title: First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer
  publication-title: Cancer Med
– volume: 3
  start-page: 175
  year: 2020
  ident: ref71
  article-title: Roles of the RET Proto-oncogene in Cancer and Development
  publication-title: JMA J
– volume: 68
  start-page: 394
  year: 2018
  ident: ref4
  article-title: Globocan 2018: Lung Cancer. International Agency for Research on Cancer
  publication-title: CA Cancer J Clin
– volume: 27
  start-page: 281
  year: 2016
  ident: ref80
  article-title: Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
  publication-title: Ann Oncol
– volume: 30
  start-page: 172
  year: 2012
  ident: ref13
  article-title: Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer
  publication-title: J Clin Oncol
– volume: 13
  start-page: 1138
  year: 2018
  ident: ref26
  article-title: A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
  publication-title: J Thorac Oncol
– volume: 393
  start-page: 1819
  year: 2019
  ident: ref93
  article-title: Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
  publication-title: Lancet
– volume: 38
  start-page: 9504
  year: 2020
  ident: ref82
  article-title: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01
  publication-title: J Clin Oncol
– volume: 377
  start-page: 829
  year: 2017
  ident: ref54
  article-title: Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
– volume: 31
  start-page: 1693
  year: 2020
  ident: ref84
  article-title: NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents
  publication-title: Ann Oncol
– volume: 350
  start-page: 351
  year: 2004
  ident: ref6
  article-title: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer
  publication-title: N Engl J Med
– volume: 38
  start-page: 9501
  year: 2020
  ident: ref102
  article-title: Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA
  publication-title: J Clin Oncol
– volume: 38
  start-page: 9513
  year: 2020
  ident: ref47
  article-title: ECOG-ACRIN 5162: A phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions
  publication-title: J Clin Oncol
– volume: 372
  start-page: 2018
  year: 2015
  ident: ref105
  article-title: Pembrolizumab for the treatment of non-small-cell lung cancer
  publication-title: N Engl J Med
– volume: 352
  start-page: 2589
  year: 2005
  ident: ref9
  article-title: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer
  publication-title: N Engl J Med
– volume: 374
  start-page: 379
  year: 2009
  ident: ref15
  article-title: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
  publication-title: Lancet
– volume: 38
  start-page: 9514
  year: 2020
  ident: ref49
  article-title: Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients
  publication-title: J Clin Oncol
– volume: 15
  start-page: 5216
  year: 2009
  ident: ref52
  article-title: Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population
  publication-title: Clin Cancer Res
– volume: 21
  start-page: 261
  year: 2020
  ident: ref64
  article-title: Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
  publication-title: Lancet Oncol
– volume: 15
  start-page: 1236
  year: 2014
  ident: ref42
  article-title: Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
  publication-title: Lancet Oncol
– volume: 7
  start-page: 241
  year: 2006
  ident: ref107
  article-title: Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer
  publication-title: Clin Lung Cancer
– volume: 26
  start-page: 1877
  year: 2015
  ident: ref31
  article-title: Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
  publication-title: Ann Oncol
– volume: 8
  start-page: 561
  year: 2017
  ident: ref90
  article-title: PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
  publication-title: Front Pharmacol
– volume: 30
  start-page: 447
  year: 2019
  ident: ref83
  article-title: HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
  publication-title: Ann Oncol
– volume: 28
  start-page: 2443
  year: 2017
  ident: ref33
  article-title: First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
  publication-title: Ann Oncol
– volume: 37
  start-page: 9001
  year: 2019
  ident: ref41
  article-title: Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef+C)
  publication-title: J Clin Oncol
– volume: 31
  start-page: 1056
  year: 2020
  ident: ref55
  article-title: Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
  publication-title: Ann Oncol
– volume: 378
  start-page: 113
  year: 2018
  ident: ref35
  article-title: Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
– volume: 172
  start-page: 523
  year: 2005
  ident: ref1
  article-title: One hundred years of lung cancer
  publication-title: Am J Respir Crit Care Med
– volume: 28
  start-page: 3138
  year: 2010
  ident: ref12
  article-title: Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer
  publication-title: J Clin Oncol
– volume: 37
  start-page: 9092
  year: 2019
  ident: ref58
  article-title: Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC)
  publication-title: J Clin Oncol
– volume: 383
  start-page: 1711
  year: 2020
  ident: ref19
  article-title: Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
– volume: 38
  start-page: 9515
  year: 2020
  ident: ref74
  article-title: Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC)
  publication-title: J Clin Oncol
– volume: 378
  start-page: 2288
  year: 2018
  ident: ref100
  article-title: Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
  publication-title: N Engl J Med
– volume: 18
  start-page: 1307
  year: 2017
  ident: ref75
  article-title: Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
  publication-title: Lancet Oncol
– volume: 4
  start-page: 411
  year: 2020
  ident: ref81
  article-title: Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review
  publication-title: JCO Precis Oncol
– volume: 9
  start-page: 2800
  year: 2020
  ident: ref116
  article-title: Medical oncologist perspectives on palliative care reveal physician-centered barriers to early integration
  publication-title: Ann Palliat Med
– volume: 390
  start-page: 29
  year: 2017
  ident: ref57
  article-title: Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
  publication-title: Lancet
– volume: 379
  start-page: 2027
  year: 2018
  ident: ref59
  article-title: Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
– volume: 5
  start-page: 1365
  year: 1999
  ident: ref89
  article-title: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
  publication-title: Nat Med
– volume: 383
  start-page: 2018
  year: 2020
  ident: ref61
  article-title: First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
  publication-title: N Engl J Med
– volume: 31
  start-page: 289
  year: 2020
  ident: ref76
  article-title: Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
  publication-title: Ann Oncol
– volume: 375
  start-page: 1823
  year: 2016
  ident: ref91
  article-title: Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
– volume: 32
  start-page: 757
  year: 2018
  ident: ref109
  article-title: Differential effects of early palliative care based on the age and sex of patients with advanced cancer from a randomized controlled trial
  publication-title: Palliat Med
– volume: 379
  start-page: 2040
  year: 2018
  ident: ref98
  article-title: Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
– volume: 13
  start-page: 59
  year: 2014
  ident: ref114
  article-title: Attitudes and referral patterns of lung cancer specialists in Europe to Specialized Palliative Care (SPC) and the practice of Early Palliative Care (EPC)
  publication-title: BMC Palliat Care
– volume: 16
  start-page: 141
  year: 2015
  ident: ref27
  article-title: Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
  publication-title: Lancet Oncol
– volume: 378
  start-page: 2078
  year: 2018
  ident: ref96
  article-title: Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
– volume: 383
  start-page: 813
  year: 2020
  ident: ref73
  article-title: Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
– volume: 36
  start-page: 9007
  year: 2018
  ident: ref43
  article-title: Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567
  publication-title: J Clin Oncol
– volume: 362
  start-page: 2380
  year: 2010
  ident: ref28
  article-title: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
  publication-title: N Engl J Med
– volume: 7
  start-page: 719
  year: 2006
  ident: ref7
  article-title: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
  publication-title: Lancet Oncol
– volume: 19
  start-page: 4273
  year: 2013
  ident: ref53
  article-title: ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer
  publication-title: Clin Cancer Res
– volume: 371
  start-page: 1963
  year: 2014
  ident: ref63
  article-title: Crizotinib in ROS1-rearranged non-small-cell lung cancer
  publication-title: N Engl J Med
– volume: 377
  start-page: 1919
  year: 2017
  ident: ref21
  article-title: Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
  publication-title: N Engl J Med
– volume: 18
  start-page: 1454
  year: 2017
  ident: ref34
  article-title: Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
  publication-title: Lancet Oncol
– volume: 34
  start-page: e141
  year: 2016
  ident: ref72
  article-title: Effect of the RET inhibitor vandetanib in a patient with RET fusion-positive metastatic non-small-cell lung cancer
  publication-title: J Clin Oncol
– volume: 20
  start-page: 625
  year: 2019
  ident: ref38
  article-title: Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
  publication-title: Lancet Oncol
– volume: 36
  start-page: 36
  year: 2018
  ident: ref117
  article-title: Prognostic understanding and barriers to palliative care in patients with metastatic lung cancer on immunotherapy
  publication-title: J Clin Oncol
– volume: 38
  start-page: 124
  year: 2020
  ident: ref39
  article-title: Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer
  publication-title: J Clin Oncol
– volume: 38
  year: 2020
  ident: ref25
  article-title: ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC
  publication-title: J Clin Oncol
– ident: 2023030804370732000_375.nov09_3.n2363.55
  doi: 10.1016/j.annonc.2020.04.478
– ident: 2023030804370732000_375.nov09_3.n2363.34
  doi: 10.1016/S1470-2045(17)30608-3
– ident: 2023030804370732000_375.nov09_3.n2363.19
  doi: 10.1056/NEJMoa2027071
– ident: 2023030804370732000_375.nov09_3.n2363.92
  doi: 10.1200/JCO.18.00149
– ident: 2023030804370732000_375.nov09_3.n2363.97
  doi: 10.1200/JCO.19.03136
– ident: 2023030804370732000_375.nov09_3.n2363.61
  doi: 10.1056/NEJMoa2027187
– ident: 2023030804370732000_375.nov09_3.n2363.70
  doi: 10.1093/annonc/mdy334
– ident: 2023030804370732000_375.nov09_3.n2363.43
  doi: 10.1200/JCO.2018.36.15_suppl.9007
– ident: 2023030804370732000_375.nov09_3.n2363.29
  doi: 10.1016/S1470-2045(11)70393-X
– ident: 2023030804370732000_375.nov09_3.n2363.90
  doi: 10.3389/fphar.2017.00561
– ident: 2023030804370732000_375.nov09_3.n2363.45
  doi: 10.1007/s00262-020-02714-5
– ident: 2023030804370732000_375.nov09_3.n2363.62
– ident: 2023030804370732000_375.nov09_3.n2363.46
  doi: 10.1093/annonc/mdz077
– ident: 2023030804370732000_375.nov09_3.n2363.39
  doi: 10.1200/JCO.19.01154
– ident: 2023030804370732000_375.nov09_3.n2363.53
  doi: 10.1158/1078-0432.CCR-13-0318
– ident: 2023030804370732000_375.nov09_3.n2363.78
  doi: 10.1016/j.lungcan.2014.06.007
– ident: 2023030804370732000_375.nov09_3.n2363.30
  doi: 10.1016/S1470-2045(11)70184-X
– ident: 2023030804370732000_375.nov09_3.n2363.9
  doi: 10.1056/NEJMoa043623
– ident: 2023030804370732000_375.nov09_3.n2363.71
  doi: 10.31662/jmaj.2020-0021
– ident: 2023030804370732000_375.nov09_3.n2363.101
  doi: 10.1056/NEJMoa1910231
– ident: 2023030804370732000_375.nov09_3.n2363.59
  doi: 10.1056/NEJMoa1810171
– ident: 2023030804370732000_375.nov09_3.n2363.103
  doi: 10.1200/JCO.2020.38.15_suppl.9500
– ident: 2023030804370732000_375.nov09_3.n2363.105
  doi: 10.1056/NEJMoa1501824
– ident: 2023030804370732000_375.nov09_3.n2363.7
  doi: 10.1016/S1470-2045(06)70804-X
– volume: 31
  start-page: S1142
  year: 2020
  ident: 2023030804370732000_375.nov09_3.n2363.48
  article-title: LBA60 - ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.08.2293
– ident: 2023030804370732000_375.nov09_3.n2363.75
  doi: 10.1016/S1470-2045(17)30679-4
– ident: 2023030804370732000_375.nov09_3.n2363.8
  doi: 10.1200/JCO.2007.13.9030
– ident: 2023030804370732000_375.nov09_3.n2363.23
  doi: 10.1016/j.jtho.2020.12.015
– ident: 2023030804370732000_375.nov09_3.n2363.87
  doi: 10.1002/cam4.2972
– ident: 2023030804370732000_375.nov09_3.n2363.85
  doi: 10.1056/NEJMoa1917239
– ident: 2023030804370732000_375.nov09_3.n2363.52
  doi: 10.1158/1078-0432.CCR-09-0802
– ident: 2023030804370732000_375.nov09_3.n2363.94
  doi: 10.1093/annonc/mdx091.063
– ident: 2023030804370732000_375.nov09_3.n2363.27
  doi: 10.1016/S1470-2045(14)71173-8
– ident: 2023030804370732000_375.nov09_3.n2363.12
  doi: 10.1200/JCO.2009.27.6204
– ident: 2023030804370732000_375.nov09_3.n2363.16
  doi: 10.1016/S0140-6736(15)60294-X
– ident: 2023030804370732000_375.nov09_3.n2363.93
  doi: 10.1016/S0140-6736(18)32409-7
– ident: 2023030804370732000_375.nov09_3.n2363.63
  doi: 10.1056/NEJMoa1406766
– ident: 2023030804370732000_375.nov09_3.n2363.117
  doi: 10.1200/JCO.2018.36.34_suppl.36
– ident: 2023030804370732000_375.nov09_3.n2363.68
  doi: 10.1200/JCO.2020.38.15_suppl.9509
– ident: 2023030804370732000_375.nov09_3.n2363.56
  doi: 10.1016/j.jtho.2019.03.007
– ident: 2023030804370732000_375.nov09_3.n2363.54
  doi: 10.1056/NEJMoa1704795
– ident: 2023030804370732000_375.nov09_3.n2363.40
  doi: 10.1200/JCO.19.01488
– ident: 2023030804370732000_375.nov09_3.n2363.112
  doi: 10.1007/s00520-018-4184-3
– ident: 2023030804370732000_375.nov09_3.n2363.114
  doi: 10.1186/1472-684X-13-59
– ident: 2023030804370732000_375.nov09_3.n2363.1
  doi: 10.1164/rccm.200504-531OE
– ident: 2023030804370732000_375.nov09_3.n2363.41
  doi: 10.1200/JCO.2019.37.15_suppl.9001
– ident: 2023030804370732000_375.nov09_3.n2363.74
  doi: 10.1200/JCO.2020.38.15_suppl.9515
– ident: 2023030804370732000_375.nov09_3.n2363.108
  doi: 10.1001/jama.2009.1198
– ident: 2023030804370732000_375.nov09_3.n2363.110
  doi: 10.1056/NEJMoa1000678
– ident: 2023030804370732000_375.nov09_3.n2363.88
  doi: 10.1002/j.1460-2075.1992.tb05481.x
– ident: 2023030804370732000_375.nov09_3.n2363.77
  doi: 10.1200/JCO.2018.77.9777
– ident: 2023030804370732000_375.nov09_3.n2363.81
  doi: 10.1200/PO.19.00333
– ident: 2023030804370732000_375.nov09_3.n2363.42
  doi: 10.1016/S1470-2045(14)70381-X
– ident: 2023030804370732000_375.nov09_3.n2363.109
  doi: 10.1177/0269216317751893
– ident: 2023030804370732000_375.nov09_3.n2363.100
  doi: 10.1056/NEJMoa1716948
– ident: 2023030804370732000_375.nov09_3.n2363.20
  doi: 10.1016/j.jtho.2021.01.320
– ident: 2023030804370732000_375.nov09_3.n2363.66
  doi: 10.1200/JCO.2018.77.7326
– ident: 2023030804370732000_375.nov09_3.n2363.82
  doi: 10.1200/JCO.2020.38.15_suppl.9504
– ident: 2023030804370732000_375.nov09_3.n2363.25
  doi: 10.1200/JCO.2020.38.15_suppl.TPS9077
– ident: 2023030804370732000_375.nov09_3.n2363.73
  doi: 10.1056/NEJMoa2005653
– ident: 2023030804370732000_375.nov09_3.n2363.76
  doi: 10.1016/j.annonc.2019.10.022
– ident: 2023030804370732000_375.nov09_3.n2363.44
  doi: 10.1001/jamaoncol.2020.6758
– ident: 2023030804370732000_375.nov09_3.n2363.113
  doi: 10.1093/annonc/mdr345
– ident: 2023030804370732000_375.nov09_3.n2363.4
  doi: 10.3322/caac.21492
– ident: 2023030804370732000_375.nov09_3.n2363.116
  doi: 10.21037/apm-20-270
– ident: 2023030804370732000_375.nov09_3.n2363.10
  doi: 10.1200/JCO.2005.04.6110
– ident: 2023030804370732000_375.nov09_3.n2363.31
  doi: 10.1093/annonc/mdv276
– ident: 2023030804370732000_375.nov09_3.n2363.96
  doi: 10.1056/NEJMoa1801005
– ident: 2023030804370732000_375.nov09_3.n2363.49
  doi: 10.1200/JCO.2020.38.15_suppl.9514
– ident: 2023030804370732000_375.nov09_3.n2363.6
  doi: 10.1056/NEJMoa031644
– ident: 2023030804370732000_375.nov09_3.n2363.13
  doi: 10.1200/JCO.2010.33.7089
– ident: 2023030804370732000_375.nov09_3.n2363.3
  doi: 10.3322/caac.21492
– ident: 2023030804370732000_375.nov09_3.n2363.91
  doi: 10.1056/NEJMoa1606774
– ident: 2023030804370732000_375.nov09_3.n2363.38
  doi: 10.1016/S1470-2045(19)30035-X
– ident: 2023030804370732000_375.nov09_3.n2363.84
  doi: 10.1016/j.annonc.2020.08.2335
– ident: 2023030804370732000_375.nov09_3.n2363.106
  doi: 10.1200/JCO.20.00131
– ident: 2023030804370732000_375.nov09_3.n2363.28
  doi: 10.1056/NEJMoa0909530
– ident: 2023030804370732000_375.nov09_3.n2363.115
  doi: 10.1177/1049909120973200
– volume: 1
  start-page: 63
  year: 2011
  ident: 2023030804370732000_375.nov09_3.n2363.5
  article-title: Stereotactic body radiotherapy for stage I non-small cell lung cancer
  publication-title: J Radiosurg SBRT
– ident: 2023030804370732000_375.nov09_3.n2363.21
  doi: 10.1056/NEJMoa1709937
– ident: 2023030804370732000_375.nov09_3.n2363.24
  doi: 10.1002/cncr.33083
– ident: 2023030804370732000_375.nov09_3.n2363.80
  doi: 10.1093/annonc/mdv573
– ident: 2023030804370732000_375.nov09_3.n2363.83
  doi: 10.1093/annonc/mdy542
– ident: 2023030804370732000_375.nov09_3.n2363.98
  doi: 10.1056/NEJMoa1810865
– ident: 2023030804370732000_375.nov09_3.n2363.14
  doi: 10.1016/S0140-6736(13)62159-5
– ident: 2023030804370732000_375.nov09_3.n2363.2
  doi: 10.1055/s-0033-1342949
– ident: 2023030804370732000_375.nov09_3.n2363.33
  doi: 10.1093/annonc/mdx359
– ident: 2023030804370732000_375.nov09_3.n2363.37
  doi: 10.1016/S1470-2045(19)30634-5
– ident: 2023030804370732000_375.nov09_3.n2363.99
  doi: 10.1016/S1470-2045(19)30167-6
– ident: 2023030804370732000_375.nov09_3.n2363.17
  doi: 10.1056/NEJMoa1716078
– ident: 2023030804370732000_375.nov09_3.n2363.15
  doi: 10.1016/S0140-6736(09)60737-6
– ident: 2023030804370732000_375.nov09_3.n2363.111
  doi: 10.1016/j.jpainsymman.2016.01.003
– ident: 2023030804370732000_375.nov09_3.n2363.89
  doi: 10.1038/70932
– ident: 2023030804370732000_375.nov09_3.n2363.104
  doi: 10.1056/NEJMoa1503093
– ident: 2023030804370732000_375.nov09_3.n2363.58
  doi: 10.1200/JCO.2019.37.15_suppl.9092
– ident: 2023030804370732000_375.nov09_3.n2363.26
  doi: 10.1016/j.jtho.2018.03.035
– ident: 2023030804370732000_375.nov09_3.n2363.72
  doi: 10.1200/JCO.2013.50.5016
– ident: 2023030804370732000_375.nov09_3.n2363.47
  doi: 10.1200/JCO.2020.38.15_suppl.9513
– ident: 2023030804370732000_375.nov09_3.n2363.51
  doi: 10.1200/JCO.2020.38.15_suppl.9512
– ident: 2023030804370732000_375.nov09_3.n2363.67
  doi: 10.1093/annonc/mdy424.090
– ident: 2023030804370732000_375.nov09_3.n2363.102
  doi: 10.1200/JCO.2020.38.15_suppl.9501
– ident: 2023030804370732000_375.nov09_3.n2363.18
  doi: 10.1200/JCO.2011.39.4882
– ident: 2023030804370732000_375.nov09_3.n2363.64
  doi: 10.1016/S1470-2045(19)30690-4
– ident: 2023030804370732000_375.nov09_3.n2363.65
  doi: 10.1200/JCO.2016.71.3701
– ident: 2023030804370732000_375.nov09_3.n2363.107
  doi: 10.3816/CLC.2006.n.001
– ident: 2023030804370732000_375.nov09_3.n2363.86
  doi: 10.1093/annonc/mdz131
– ident: 2023030804370732000_375.nov09_3.n2363.35
  doi: 10.1056/NEJMoa1713137
– ident: 2023030804370732000_375.nov09_3.n2363.50
  doi: 10.1200/JCO.2020.38.15_suppl.9580
– ident: 2023030804370732000_375.nov09_3.n2363.36
  doi: 10.1056/NEJMoa1913662
– ident: 2023030804370732000_375.nov09_3.n2363.57
  doi: 10.1016/S0140-6736(17)30565-2
– ident: 2023030804370732000_375.nov09_3.n2363.95
  doi: 10.1016/S0140-6736(21)00228-2
– ident: 2023030804370732000_375.nov09_3.n2363.22
  doi: 10.1200/JCO.2019.37.15_suppl.8526
– ident: 2023030804370732000_375.nov09_3.n2363.11
  doi: 10.1016/j.annonc.2020.08.2280
– ident: 2023030804370732000_375.nov09_3.n2363.60
  doi: 10.1200/JCO.20.00505
– ident: 2023030804370732000_375.nov09_3.n2363.69
  doi: 10.1056/NEJMoa2004407
– ident: 2023030804370732000_375.nov09_3.n2363.79
  doi: 10.4143/crt.2019.186
– ident: 2023030804370732000_375.nov09_3.n2363.32
  doi: 10.1093/annonc/mdv270
SSID ssj0002378965
Score 2.6981637
SecondaryResourceType review_article
Snippet ABSTRACTLung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell...
Lung cancer remains a leading cause of cancer related mortality worldwide. Despite numerous advances in treatments over the past decade, non-small cell lung...
SourceID proquest
crossref
bmj
SourceType Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage n2363
SubjectTerms 20th century
Cancer therapies
Chemoradiotherapy
Chemotherapy
Clinical medicine
Clinical Review
Clinical trials
Cytotoxicity
Immunotherapy
Lung cancer
Metastasis
Mutation
Non-small cell lung carcinoma
Patients
Radiation therapy
Small cell lung carcinoma
Surgery
Title Advances in systemic therapy for non-small cell lung cancer
URI https://bmj.com/content/375/bmj.n2363.full
https://www.proquest.com/docview/2595858351
https://www.proquest.com/docview/2596013293
Volume 375
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bS8MwFA5uA_FFvOJ0jig--BLXNm2a4oNM2RjChoiDvY0mTWHSXdzlwX_vOW22MRi-lfY0gZPT5DuXfoeQB0elyk38lCklHeabSDDwsyRToS-SOHZCE2NAv9sTnb7_PggGNuC2sGWV6z0x36iTqcYYeQNgOiBbwAvuy-yHYdcozK7aFholUkHqMizpCgfhJsbi8VBGIrCEQi4XDTX-fpp4HEk_S3C9exjt7sX5AdM-IccWGdJmsZSn5MBMzshh1-a-z8lzs0jXL-hoQgsC5pGmxf9TvxSwJwVPni3GcZZRDMfTDL5jqvGV-QXpt1tfbx1mWx8wxT1nybgI_DQ0voqTQCPskqFUiat0wqM04loBUPGkkZFUXiS5I3USGEdLbkQqQ5C4JGWY1FwRCg5ODCBPYT2bH8OQgGGEdtOcud54QZXUQRNDa7qLYe4VcDHEm7mqquRxraShtsTh2L8i2yd6vxGdFWwZ-4Rqa01vZ90ub5XcbR6DqaPC4omZrnIZgamhiF__P8QNOfKw9ASjv1GNlJfzlbkF7LBU9dxA6qTy2up9fP4BFdbEow
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dS9xAEB_0hNqXUq2lZ61dpQVftia7yWaDiFg_OD_uEFHwLc1uNmC5y53eifhP-Tc6k48TQXzzLSSTXZidnf3Nx84A_PJMbvwsyLkx2uOBixVHO0tzEwUqS1Mvcik59Ls91bkMjq_Cqxl4bO7CUFploxNLRZ0NLfnINxGmI7JFvODvjG44dY2i6GrTQqMSixP3cI8m23j7aB_X97cQhwcXex1edxXgRgpvwqUKgzxygUmz0BKi0ZE2mW9sJuM8ltYgBhDa6VgbEWvpaZuFzrNaOpXrKKfiS6jy5wKJpkwL5v4e9M7Op14dISMdq7AuYeRLtWkG__8UQlKZ0Vl8fnn8vdT-5ZF2-Bk-1ViU7VbCswAzrliED9062v4FtnarBIExuy5YVfL52rLqxtYDQ7TLimHBx4O032cUAGB91BzM0i-3S3D5Lmz5Ci2c1H0DhiZVirDSUAZdkOKQiJqU9fOyVr4TYRtWkRNJvVnGSWmHSJXQy5JVbdhomJTYulQ5dczov0a6PiUdVfU5XiNaaTj9POuzQLVhbfoZNxcxLC3c8K6kURSMiuXy20P8hPnORfc0OT3qnXyHj4ISX8j3HK9Aa3J7534gcpmY1VpcGPx7bwl9AoXLAPk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3dS9xAEB-sBelL0Wrx6tdWWvBle8lusruhiIj20FrFB4V7i9nNBpQzp94dcv-af11n8nEiiG--hWSyGyazs7_52BmAH4EtbJhHBbfWBDzyieJoZxludaTyLAu0z8ihf3qmji6jv_24PwdP7VkYSqtsdWKlqPOhIx95F2E6IlvEC2G3aNIizg97e3f3nDpIUaS1badRi8iJnz6i-TbaPT7Ef_1TiN6fi4Mj3nQY4FaKYMyliqNC-8hmeewI3RhtbB5al8ukSKSziAeE8SYxViRGBsblsQ-ckV4VRhdUiAnV_0eNX0VrTPf1zL8jpDaJiptiRqFUXXt786sUkgqOfsDrlxvhy32g2tx6i_C5QaVsvxajJZjz5RdYOG3i7svwe79OFRix65LVxZ-vHavPbk0Z4l5WDks-us0GA0ahADZAHcIcvfKwApfvwpSvMI-T-lVgaFxlCDAt5dJFGQ6J-Em5sKiq5nsRd2ATOZE2y2aUVhaJVCndrFjVgZ2WSalripZT74zBa6TbM9K7ulLHa0TrLaefZ30WrQ58nz3GZUYMy0o_nFQ0isJSifz29hBbsIBymf47PjtZg0-CMmDICZ2sw_z4YeI3EMKM7WYlKwyu3ls4_wPG3QPJ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advances+in+systemic+therapy+for+non-small+cell+lung+cancer&rft.jtitle=BMJ.+British+medical+journal+%28Clinical+research+ed.%29&rft.au=Miller%2C+Meagan&rft.au=Hanna%2C+Nasser&rft.date=2021-11-09&rft.issn=1756-1833&rft.eissn=1756-1833&rft.spage=n2363&rft_id=info:doi/10.1136%2Fbmj.n2363&rft.externalDBID=n%2Fa&rft.externalDocID=10_1136_bmj_n2363
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-1833&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-1833&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-1833&client=summon